|
1）Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinsonʼs disease. Nat Med. 2008; 14: 504-6
|
|
|
|
2）Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinsonʼs disease suggest host-to-graft disease propagation. Nat Med. 2008; 14: 501-3
|
|
|
|
|
|
3）Kordower JH, Chu Y, Hauser RA, et al. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008; 23: 2303-6
|
|
|
|
|
|
4）Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinsonʼs disease. Neurobiol Aging. 2003; 24: 197-211
|
|
|
|
|
|
5）Mougenot AL, Bencsik A, Nicot S, et al. Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated alpha-synuclein. J Neuropathol Exp Neurol. 2011; 70: 377-85
|
|
|
|
|
|
6）Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012; 209: 975-86
|
|
|
|
|
|
7）Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013; 136: 1128-38
|
|
|
|
|
|
8）Freundt EC, Maynard N, Clancy EK, et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol. 2012; 72: 517-24
|
|
|
|
|
|
9）Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011; 72: 57-71
|
|
|
|
|
|
10）Konno M, Hasegawa T, Baba T, et al. Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener. 2012; 7: 38
|
|
|
|
|
|
11）Sung JY, Kim J, Paik SR, et al. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem. 2001; 276: 27441-8
|
|
|
|
|
|
12）Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010; 285: 9262-72
|
|
|
|
|
|
13）Lee HJ, Suk JE, Bae EJ, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008; 40: 1835-49
|
|
|
|
|
|
14）Sugeno N, Hasegawa T, Tanaka N, et al. Lys-63-linked ubiquitination by E3 ubiquitin ligase Nedd4-1 facilitates endosomal sequestration of internalized alpha-synuclein. J Biol Chem. 2014; 289: 18137-51
|
|
|
|
|
|
15）Fevrier B, Vilette D, Archer F, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A. 2004; 101: 9683-8
|
|
|
|
|
|
16）Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010; 30: 6838-51
|
|
|
|
|
|
17）Hasegawa T, Konno M, Baba T, et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of alpha-synuclein. PLoS One. 2011; 6: e29460
|
|
|
|
|
|
18）Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012; 7: 42
|
|
|
|
|
|
19）Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012; 2: 898
|
|
|
|
|
|
20）Bae EJ, Yang NY, Song M, et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat Commun. 2014; 5: 4755
|
|
|
|
|
|
21）Tsunemi T, Hamada K, Krainc D. ATP13A2/PARK9 regulates secretion of exosomes and alpha-synuclein. J Neurosci. 2014; 34: 15281-7
|
|
|
|
|
|
22）Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305: 1292-5
|
|
|
|
|
|
23）Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy. 2015: 11: 1443-57
|
|
|
|
|
|
24）Usenovic M, Tresse E, Mazzulli JR, et al. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci. 2012; 32: 4240-6
|
|
|
|
|
|
25）Perrett RM, Alexopoulou Z, Tofaris GK. The endosomal pathway in Parkinsonʼs disease. Mol Cell Neurosci. 2015; 66: 21-8
|
|
|
|
|
|
26）Miura E, Hasegawa T, Konno M, et al. VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinsonʼs disease. Neurobiol Dis. 2014; 71c: 1-13
|
|
|
|
|
|
27）Reyes JF, Rey NL, Bousset L, et al. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014; 62: 387-98
|
|
|
|
|
|
28）Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012; 32: 13454-69
|
|
|
|
|
|
29）Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011; 6: e19338
|
|
|
|
|
|
30）Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015; 10: 10
|
|
|
|
|
|
31）Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinsonʼs disease-like models. J Neurosci. 2014; 34: 9441-54
|
|
|
|
|
|
32）Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinsonʼs disease clinical trials. Acta Neuropathol. 2014; 127: 861-79
|
|
|
|
|
|
33）Lindstrom V, Ihse E, Fagerqvist T, et al. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinsonʼs disease and other Lewy body disorders. Immunotherapy. 2014; 6: 141-53
|
|
|
|
|